457 related articles for article (PubMed ID: 33057388)
1. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
[TBL] [Abstract][Full Text] [Related]
2. Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension.
Sun XQ; Peters EL; Schalij I; Axelsen JB; Andersen S; Kurakula K; Gomez-Puerto MC; Szulcek R; Pan X; da Silva Goncalves Bos D; Schiepers REJ; Andersen A; Goumans MJ; Vonk Noordegraaf A; van der Laarse WJ; de Man FS; Bogaard HJ
Am J Respir Cell Mol Biol; 2021 Mar; 64(3):331-343. PubMed ID: 33264068
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacological characteristics and clinical study results of Selexipag (Uptravi
Kuwano K; Kosugi K; Fuchikami C; Funaki S
Nihon Yakurigaku Zasshi; 2021; 156(3):178-186. PubMed ID: 33952848
[TBL] [Abstract][Full Text] [Related]
4. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
Mulvaney EP; Reid HM; Bialesova L; Bouchard A; Salvail D; Kinsella BT
BMC Pulm Med; 2020 Apr; 20(1):85. PubMed ID: 32252727
[TBL] [Abstract][Full Text] [Related]
5. Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery.
Morrison K; Haag F; Ernst R; Iglarz M; Clozel M
J Pharmacol Exp Ther; 2018 Jun; 365(3):727-733. PubMed ID: 29588339
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of right coronary vascular dysfunction in severe pulmonary hypertensive rats using synchrotron radiation microangiography.
Inagaki T; Pearson JT; Tsuchimochi H; Schwenke DO; Saito S; Higuchi T; Masaki T; Umetani K; Shirai M; Nakaoka Y
Am J Physiol Heart Circ Physiol; 2021 Mar; 320(3):H1021-H1036. PubMed ID: 33481696
[TBL] [Abstract][Full Text] [Related]
7. The Isoquinoline-Sulfonamide Compound H-1337 Attenuates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Rats.
Shoji H; Yoshida Y; Sanada TJ; Naito A; Maruyama J; Zhang E; Sumi K; Sakao S; Maruyama K; Hidaka H; Tatsumi K
Cells; 2021 Dec; 11(1):. PubMed ID: 35011628
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
Rol N; de Raaf MA; Sun XQ; Kuiper VP; da Silva Gonçalves Bos D; Happé C; Kurakula K; Dickhoff C; Thuillet R; Tu L; Guignabert C; Schalij I; Lodder K; Pan X; Herrmann FE; van Nieuw Amerongen GP; Koolwijk P; Vonk-Noordegraaf A; de Man FS; Wollin L; Goumans MJ; Szulcek R; Bogaard HJ
Cardiovasc Res; 2019 Feb; 115(2):432-439. PubMed ID: 30032282
[TBL] [Abstract][Full Text] [Related]
9. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
[TBL] [Abstract][Full Text] [Related]
10. A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries.
Fuchikami C; Murakami K; Tajima K; Homan J; Kosugi K; Kuramoto K; Oka M; Kuwano K
Eur J Pharmacol; 2017 Jan; 795():75-83. PubMed ID: 27919660
[TBL] [Abstract][Full Text] [Related]
11. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S
J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S
Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826
[TBL] [Abstract][Full Text] [Related]
13. Natural reversal of pulmonary vascular remodeling and right ventricular remodeling in SU5416/hypoxia-treated Sprague-Dawley rats.
Zungu-Edmondson M; Shults NV; Melnyk O; Suzuki YJ
PLoS One; 2017; 12(8):e0182551. PubMed ID: 28809956
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of mesenchymal stem cell delivery via a novel cardiac bioscaffold on right ventricles of pulmonary arterial hypertensive rats.
Schmuck EG; Hacker TA; Schreier DA; Chesler NC; Wang Z
Am J Physiol Heart Circ Physiol; 2019 May; 316(5):H1005-H1013. PubMed ID: 30822119
[TBL] [Abstract][Full Text] [Related]
15. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
[TBL] [Abstract][Full Text] [Related]
16. Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome.
Demerouti EA; Karyofyllis P; Apostolopoulou SC
Can J Cardiol; 2021 Aug; 37(8):1286-1288. PubMed ID: 33539988
[TBL] [Abstract][Full Text] [Related]
17. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
Honorato Pérez J
Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
[TBL] [Abstract][Full Text] [Related]
18. Perillyl alcohol suppresses monocrotaline-induced pulmonary arterial hypertension in rats via anti-remodeling, anti-oxidant, and anti-inflammatory effects.
Beik A; Najafipour H; Joukar S; Rajabi S; Iranpour M; Kordestani Z
Clin Exp Hypertens; 2021 Apr; 43(3):270-280. PubMed ID: 33322932
[No Abstract] [Full Text] [Related]
19. Selexipag for the treatment of pulmonary arterial hypertension.
Richter MJ; Gall H; Grimminger J; Grimminger F; Ghofrani HA
Expert Opin Pharmacother; 2016 Sep; 17(13):1825-34. PubMed ID: 27467883
[TBL] [Abstract][Full Text] [Related]
20. Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.
Hansmann G; Meinel K; Bukova M; Chouvarine P; Wåhlander H; Koestenberger M;
J Heart Lung Transplant; 2020 Jul; 39(7):695-706. PubMed ID: 32362477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]